Melanotan II

Melanotan II is an unlicensed synthetic peptide that stimulates melanocortin receptors to produce skin tanning. It is not FDA-approved for any indication and has never been through formal clinical development. The peptide is typically sold as a research chemical and administered via subcutaneous injection or nasal spray.

Safety signals have escalated significantly. A September 2025 case report in the International Journal of Oral and Maxillofacial Surgery linked Melanotan II nasal spray to oral mucosal malignant melanoma in a 22-year-old, the first documented case of this association. The Skin Cancer Foundation issued a formal warning in July 2026 about the peptide's use.

Known adverse effects include severe nausea, flushing, spontaneous penile erections (priapism requiring emergency treatment), and new or changing moles. The melanoma risk is biologically plausible: Melanotan II stimulates melanocyte proliferation through melanocortin-1 receptor agonism, the same pathway involved in melanoma development.

Melanotan II remains FDA Category 2 and was deliberately excluded from the 2026 reclassification wave that removed approximately 12 other peptides from the Category 2 list. This exclusion was based on substantial safety concerns and represents an explicit regulatory signal that this peptide is considered dangerous.

No legitimate pharmaceutical company is developing Melanotan II. The product exists exclusively in the gray market. Consumers should treat any product marketed as a tanning peptide as unlicensed and potentially dangerous.